Richard Paul, MD
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (45.4%), travel and lodging and education — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Boston Scientific at 57.4% of the total. Reporting peaked in 2019 at $1,229 and has fallen 69.5% since, to $375 in 2025. That places this record below the midpoint for urology clinicians in DE, where the typical reported total is $2,396.
Across 47 payments — averaging $41.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$1K
- Astellas Pharma US Inc$356
- Teleflex LLC$91
- AbbVie$74
- Pfizer$46
- 180 Medical, Inc.$37
- plus $230 from 11 others
What the payments were for
- Travel & lodging$73838%
- Food & beverage$89145%
- Education$33117%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 9 | $1,126 |
| Astellas Pharma US Inc | 15 | $356 |
| Teleflex LLC | 3 | $91 |
| AbbVie | 4 | $74 |
| Pfizer | 3 | $46 |
| 180 Medical, Inc. | 2 | $37 |
| AstraZeneca | 1 | $35 |
| Novartis | 1 | $31 |
| Urogen Pharma, Inc. | 1 | $27 |
| Tolmar, Inc. | 1 | $26 |
| Merck | 1 | $23 |
| Bioprotect Medical, Inc. | 1 | $19 |
| Cycle Pharmaceuticals Inc | 1 | $18 |
| Ferring Pharmaceuticals Inc. | 1 | $18 |
| Photocure Inc | 1 | $17 |
| Profound Medical Corp. | 1 | $15 |
| Travere Therapeutics, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL BPH$915
- GENERAL ONCOLOGY$109
How this compares
$1,961 in reported general payments places this provider in the 35th percentile of 33 urology providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 115 | $119,766 |
| GemtesaVibegron | 32 | $35,661 |
| Tamsulosin Hcl | 811 | $16,002 |
| Testosterone | 59 | $10,992 |
| Solifenacin Succinate | 96 | $7,394 |
| Oxybutynin Chloride ErOxybutynin Chloride | 117 | $4,447 |
| Potassium Citrate ErPotassium Citrate | 14 | $3,902 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 16 | $3,202 |
| Tolterodine Tartrate ErTolterodine Tartrate | 20 | $2,541 |
| Ciprofloxacin Hcl | 129 | $2,246 |
| Finasteride | 135 | $2,175 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 58 | $1,485 |
| Testosterone Cypionate | 22 | $1,127 |
| Cephalexin | 120 | $968 |
| Methenamine Hippurate | 14 | $886 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $356 | $119,766115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 33 urology providers in Delaware.
Other urology in Lewes
- Christopher CaputoLewes$4K
- Ramachandra HosmaneLewes$778
- Delbert KwanLewes$688
- Elisabeth MulroyLewes$299
- Christopher MitchellWilmington$19K
- Michael LobisWilmington$8K
- Joohyong KimDover$7K
- Thomas DesperitoWilmington$7K
- Raymond BolognaMilford$7K
- Christopher VallorosiDover$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.